
Isense Medical Corporation (AKA: iSense LLC~Metabolomx) Profile last edited on: 5/2/2022
CAGE: 62QF2
UEI: T77GGNEH8HS8
Business Identifier: Diagnostic breath sensor technology Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
500 South Australian Avenue Suite 120
West Palm Beach, FL 33401
West Palm Beach, FL 33401
(561) 655-5588 |
admin@metabolomx.com |
www.metabolomx.com |
Location: Single
Congr. District: 21
County: Palm Beach
Congr. District: 21
County: Palm Beach
Public Profile
Isense Medical Corporation, AKA Metabolomx, focuses on disease diagnosis using metabolomics to directly analyze the activity of the metabolic pathways themselves by measurement of small molecule metabolites. Tumor metabolic pathways produce metabolites different than normal cells. These small molecule metabolites are volatile organic compounds (VOCs), they appear in alveolar blood, partition into the gas phase in exhaled breath producing a metabolic signature of disease in breath that can distinguished from that of healthy subjects. The company has developed technology enabling the identification of lung cancer and respiratory infection from breath.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2018 | 2 | NIH | $5,879,445 | |
Project Title: Rapid Identification of Pathogenic Bacteria and Sepsis Diagnosis | ||||
2017 | 1 | NIH | $149,914 | |
Project Title: Oxidative Stress Biosensor for Breath-Based Environmental Monitoring | ||||
2014 | 1 | NIH | $149,902 | |
Project Title: Prostate Cancer Detection Through Urine Headspace Analysis Using Colorimetric Sen | ||||
2012 | 1 | NIH | $1,124,636 | |
Project Title: Rapid Breath Detection of Lung Cancer | ||||
2012 | 1 | NIH | $137,960 | |
Project Title: Rapid Breath Detection of Colorectal Cancer with a Colorimetric Sensor Array |
Key People / Management
Paul Rhodes -- Founder and CEO
Sung Lim -- Founder and Chief Scientist
Ray A Martino -- Founder and COO
Kenneth Suslick -- Founder
Sung Lim -- Founder and Chief Scientist
Ray A Martino -- Founder and COO
Kenneth Suslick -- Founder
Company News
There are no news available.